Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 5/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27244251 | 0.79 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL29985853 | 0.79 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL14974963 | 0.77 | PRKCI (0.40) | HSP90AA1HSP90AB1MAPTALDH1A1MEN1 | |
| SCHEMBL27409455 | 0.70 | EGFR (0.35) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 | |
| SCHEMBL23599247 | 0.69 | PDPK1 (0.38) | MAPTKDM4EKMT2ANPC1HTT | |
| SCHEMBL11207240 | 0.68 | ALOX15 (0.45) | HSP90AA1HSP90AB1CTSBGPR35CTSH | |
| SCHEMBL27244271 | 0.67 | AXL (0.37) | HSP90AA1MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL1428681 | 0.66 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1CTSBGPR35MAPT | |
| SCHEMBL27409302 | 0.66 | PDPK1 (0.58) | MEN1KMT2ALMNARAB9A | |
| SCHEMBL4213047 | 0.66 | ALDH1A1 (0.34) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | HSP90AA1 4414/4885HSP90AB1 4522/4885TXNRD1 2866/4885 |
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | HSP90AA1 2612/4885HSP90AB1 2240/4885TXNRD1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.